BioWorld Asia

April 23, 2003

Celltech Brings On New CEO Following Purchase Of OGS

LONDON - It was all change last week as members of the Oxford GlycoSciences plc board resigned to make way for directors from its new owner, Celltech Group plc, and Celltech announced the appointment of its new CEO, Goran Ando. (BioWorld International) Read More

Gamma Capital Bucks Austrian Trend, Closes New Venture Round

Recombinant BCG Boosts TB Protection In Animal Studies

Affibody, InforSense Release Tool For Data Interpretation

CeNeS Sells Three Products To Strengthen Cash Position

Cellectis Licenses Technology To Nucleis For Gene Insertion

Oxford BioMedica Cuts Back On Programs To Extend Cash

Progress In Two Early Programs Gives Xenova Much-Needed Lift

French Researchers Find Gene Linked To Kindler's Syndrome

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 23, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Photo of two people shaking hands near lab equipment

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

BioWorld

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...